Angiogenesis as a therapeutic target

Similar documents
Inflammatory Cells and Metastasis

The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications

Heterotypy and Angiogenesis

The Angiopoietin Axis in Cancer

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

Processing of VEGF-C and -D by the Proprotein Convertases: Importance in Angiogenesis, Lymphangiogenesis, and Tumorigenesis

Angiogenesis in Human Development. Vascular Development

Review of relationship between vascular endothelial growth factor family & receptors and tumor angiogenesis

!!! Oncology for Scientists (RPN 530) Metastasis and Angiogenesis Chapter 13 and 14 Oct. 28 th 2014

Nintedanib in Oncology Backgrounder

LYMPHANGIOGENESIS REVIEWS THE EMERGENCE OF MOLECULAR AND TRANSGENIC LYMPHOLOGY: WHAT DO WE (REALLY) KNOW SO FAR?

VEGFR-3 in Angiogenesis and Lymphangiogenesis

Heart 3: Organogenesis, CHD, prenatal circulation

RIP-Tag2 mouse model as a Paradigm for Target. Search in NETs

Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK on tumor angiogenesis and tumor lymphangiogenesis

Microvascular rarefaction, angiogenesis and hypertension

Neoplasia 18 lecture 8. Dr Heyam Awad MD, FRCPath

Tissue repair. (3&4 of 4)

Supplementary Materials. for Garmy-Susini, et al, Integrin 4 1 signaling is required for lymphangiogenesis and tumor metastasis

Signaling Vascular Morphogenesis and Maintenance

Practice of Medicine-1 Ovarian Cancer Clinical Correlation

HEM- AND LYMPH- ANGIOGENESIS IN CANCER METASTASIS

Chapter 6. Villous Growth

PATHOBIOLOGY OF NEOPLASIA

Lymphatic Network in Cancer and Some Chemical Observations

IN VIVO ANALYSIS OF THE ROLE OF TENASCIN-C IN TUMORIGENESIS

LYMPHANGIOGENESIS REVIEWS THE RELATIONSHIP BETWEEN TUMORS AND THE LYMPHATICS: WHAT MORE IS THERE TO KNOW?

LYMPHANGIOGENESIS AND CANCER METASTASIS

Predicting benefit from antiangiogenic

Vasculogenesis, angiogenesis and lymphangiogenesis: Signaling pathways

Angiogeneza sprawa Ŝycia lub śmierci

Angiogenesis in Ovarian Cancer

Cancer as a disease of development; Developmental therapies: Anti- Angiogenesis; Stem cells and tissue regeneration.

Bevacizumab and ROP: Review of an RCT. M Chakraborty UHW

Popperian Pathways: the demarcation between quack cancer cures and scientific remedies. Michael Baum UCL November 2007

Colorectal Cancer Therapy and Associated Toxicity

The immune response against cancer

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS

Role of VEGF in angiogenesis

Mechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012

nhibitors of angiogenesis can exhibit bell-shaped and U-shaped dose-response curves: relevance for cancer therapy Dr. Andrew R.

Oxygen-independent regulation of HIF-1α levels

Cytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,

Mechanisms of Gene Regulation and Signal! Transduction in Hypoxia!

Placental Growth Factor-1 Attenuates Vascular Endothelial Growth Factor-A Dependent Tumor Angiogenesis during B Cell Carcinogenesis

DAWNING OF THE AGE OF ANGIOGENESIS

Professor Harvey White. Interventional Cardiologist Auckland

Novel Strategy of Anti-angiogenic Therapy for Uterine Cervical Carcinomas

Microenvironmental influence on angiogenesis and tumor cell survival. Mark W. Dewhirst, DVM, PhD Duke University Medical Center

Targeting angiogenesis in cancer

MICROBIOLOGY AND TUMOR BIOLOGY CENTER Karolinska Institutet, Stockholm, Sweden LYMPHANGIOGENESIS AND LYMPHATIC METASTASIS. Meit A.

Pericytes limit tumor cell metastasis

Award Number: W81XWH TITLE: PRINCIPAL INVESTIGATOR: Michael Dellinger

ANGIOGENESIS IS DEFINED as the development of

Role of VEGF in vasculogenesis and angiogenesis

Tumour vascularization: sprouting angiogenesis and beyond

2/1/2017. Agenda. David F. Williams, MD, MBA. History of Current Treatment. Current Treatment/Wet AMD Anti-VEGF Drugs. History of Current Treatment

Supplemental Material

Cancer Biology Course. Invasion and Metastasis

Supplementary Note

EPO, VEGF, chronic hypoxia adaptations and metabolism in the heart

Vascular Endothelial Growth Factors B and C: Gene Regulation and Gene Transfer In Vivo

Cell populations size is determined by rate of proliferation, Differentiation, and death by apoptosis. Figure 3-1

For personal use only

Angiogenesis and Metastasis

Hypoxia inducible factor-1α (HIF-1α) and matrix metalloproteinase 9 (MMP-9) expression in invasive breast cancer

VEGF-C/VEGFR-3 AND PDGF-B/PDGFR-ß PATHWAYS IN EMBRYONIC LYMPHANGIOGENESIS

Cancer Metronomic Therapy Milan, February 26, 2016

CD34 + VEGFR-3 + progenitor cells have a potential to differentiate towards lymphatic endothelial cells

The Role of Microenvironment in the Control of Tumor Angiogenesis

Role of Cancer Microenvironment in Metastasis: Focus on Colon Cancer

Bone Marrow Progenitor Cells and Vascular Endothelium: Studies on the In Vivo Differentiation Capacity and the Role of Bmx Tyrosine Kinase

Characterization of the Anti-angiogenic Properties of KDR-Ig4-7 and its Variants as Potential Anticancer

THE BIOLOGY OF PLATELET-GEL THERAPY

Cancer stem cells and tumor metastasis (Review)

Until recently, vascular endothelial growth factor

RESEARCH ARTICLE. Endostar Combined with Cisplatin Inhibits Tumor Growth and Lymphatic Metastasis of Lewis Lung Carcinoma Xenografts in Mice

JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T. preclinical development for cancer indications 6 and one, the vascular endothelial

The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer

B16F1 B16F10 Supplemental Figure S1

IMAGING ANGIOGENESIS. Gordon Jayson Manchester UK

TITLE: Role of Notch/VEGF-Receptor 3 in Breast Tumor Angiogenesis and Lymphangiogenesis

Vascular endothelial growth factors and their receptors in embryos, adults and in tumors

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma

Inhibiting Vascular Endothelial Growth Factor Therapeutic Implications, Perspectives and Limitations

Therapeutic Cancer Vaccines Targeting Molecules Associated with Tumor Angiogenesis

Curriculum Vitae Hui Yuan, MD

Combination Therapies Targeting PDGF and VEGF Signaling Pathways in Solid Tumors

Huiling Qiu, Lili Cao, Dan Wang, Huicheng Xu and Zhiqing Liang

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

The Sialomucin CD34 Is a Marker of Lymphatic Endothelial Cells in Human Tumors

Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future

Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2

expectancy Cancer spread to bones life expectancy

Gene Expression for VEGF-A, VEGF-C, and Their Receptors in Murine Lymphocytes and Macrophages

Vascular Endothelial Growth Factor Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma

FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/ WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: ONE CENTER EXPERIENCE RESULTS

p19/arf and p53 Suppress Sentinel Lymph Node Lymphangiogenesis and

Transcription:

Angiogenesis as a therapeutic target Lecture Experimentelle Krebsforschung SS 07 Prof. Gerhard Christofori Institute of Biochemistry and Genetics Department of Clinical-Biological Sciences University of Basel Multistage Tumorigenesis

Multistage Colorectal Carcinogenesis Tumor angiogenesis Bergers and Benjamin, 2002, Nat. Rev. Cancer

Increased microvessel density in tumors (for example ductal breast carcinoma) Vasculogenesis/Angiogenesis Carmeliet, 2003

Tumor angiogenesis in transplanted tumors Weinberg, 2006 Genetic manipulation of mice

The Rip1Tag Transgene Hanahan, Nature, 1985 Rip1Tag2 tumorigenesis

Multistage Tumorigenesis in Rip1Tag2 Transgenic Mice The angiogenic switch

Cellular Events in Tumor Angiogenesis Key Angiogenic Factors

VEGF Family Members Clinical Science www.clinsci clinsci.org Clin. Sci.. (2005) 109, 227-241 Vascular Endothelial Growth Factors and their Receptors Cross et al., TIBS, 2003

VEGFs in Vasculogenesis/Angiogenesis Hemangioblast VEGFR-2 Hematopoietic precursor Hematopoietic cells Hematopoiesis Blood cells VEGF-A VEGFR-1 VEGFR-2 Angioblast Primary vascular plexus Vasculogenesis VEGF-A VEGFR-1 Angiogenesis VEGFR-2 VEGFR-3 Enlarged embryonic vasculature (arteries & veins) Lymphangioblast VEGF-C VEGF-D VEGFR-3 EG-VEGF Endothelial differentiation Lymphangiogenesis VEGF-C VEGF-D VEGFR-3 prox-1 permeable blood vessels in steroidogenic glands tight blood vessels e.g. brain Lymphatic vessels Alitalo 2001, Stacker 1999

VEGFs and their Receptors Clinical Science www.clinsci clinsci.org Clin. Sci.. (2005) 109, 227-241 Chick CAM Assay Chorio-Allantoic-Membrane +/- VEGF-A VEGF-Knock-out heterozygous lethal!

Hypoxia-induction of VEGF-A gene expression Harris, 2001 HIF-1α regulation Harris, 2001

Harris, 2001 Vascular Endothelial Growth Factors and their Receptors

The Angiogenic Switch VEGF sequestered by ECM VEGF released by MMP activity (mast cells, Vascular Endothelial Growth Factor-A Cross et al., TIBS, 2003

Activation of Vascular Endothelial Growth Factor-A Ferrara et al., 2003 MMPs in breast (and other) tumors Egeblad and Werb, 2002

Angiogenic Factors and the ECM Sund et al., 2004 A Simplified Picture of Tumor Angiogenesis VEGFs FGFs Angiopoietins PDGF B TGFβ VEGF receptors FGF receptors Tie-2 (Tie-1?) PDGF-β receptor TGFβ receptors

Angiopoietins Jones et al., 2001 VEGFs and Angiopoietins Jones et al., 2001

The Fine Balance of Angiogenesis Regulation Bergers and Benjamin, 2002, Nat. Rev. Cancer Angiogenesis Inhibitors Endogenous Therapeutic chemicals antibodies peptides/proteins Folkman, 2004

Angiogenesis Inhibitors Cilengitide

Endogenous angiogenesis inhibitors Experimental Therapy in Rip1Tag2 Mice Interferon α/β TNP470 Angiostatin Endostatin Thrombospondin MMP inhibitors Cathepsin inhibitors Glivec (imatinib VEFR receptor inhibitors (PTK787,Sugen 6668, ) VEGF-Trap, FGF-Trap VEGF receptor antibodies Immunoliposomes Exendin-4 (GLP1R peptide) AEW471 (IGF1 receptor inhibitor) PDGF receptor inhibitors

Anti-Angiogenic Angiogenic Therapy in Rip1Tag2 Mice Bergers et al. Science 1999 Anti-Angiogenic Therapy in Rip1Tag2 Mice Weinberg, 2006

A selection of anti-angiogenic drugs approved or in clinical trials Approved for CRC first and second line VEGF-A expression and anti-vegf-a therapy (Avastin( Avastin) Hanrahan et al., 2003 Borgstrom et al., 1999

Avastin in Colorectal Cancer Hurwitz et al., 2004 Resistance to anti-angiogenic therapy?

Fibroblast Growth Factors and their Receptors Soluble Receptor Constructs Compagni et al., Cancer Res. 2000

VEGFs and FGFs are required for Tumor Angiogenesis: Rip1Tag2 tumorigenesis in vivo Compagni et al., Cancer Res. 2000 A selection of anti-angiogenic drugs approved or in clinical trials

A selection of anti-angiogenic drugs approved or in clinical trials Maturation of Vessels Pietras and Hanahan, 2005

Two Vascular Systems! Jones et al., 2001 The Lymphatic System

Lymphatic vessels Papoutsi et al. Dev. Dyn. 2001 Lymphatic vessel development Prox-1 as master control gene? Oliver and Detmar, 2002

Prox-1-induced lymphatic differentiation Petrova et al., 2002 Tumor angiogenesis and lymphangiogenesis Vasculogenesis = De novo formation of blood vessels Angiogenesis = Formation of blood vessels from pre-existing blood vessels Lymphangiogenesis = Formation of lymphatic vessels Ruoslahti, 2002

Lymphangiogenesis and angiogenesis in tumors Crnic et al., 2004 VEGF Family Members and their Receptors ANGIOGENESIS LYMPHANGIOGENESIS

Forced Lymphangiogenesis in Rip1VEGF-C Mice wt Rip1VEGF-C Mandriota et al., 2001 Forced Lymphangiogenesis in Rip1Tag2 Mice Rip1Tag2;Rip1VEGF-C LN MET Mandriota et al., 2001

Anti-angiogenic therapy ± general mechanism in solid tumors no or low resistance defined targets no angiogenesis in adults, low side effects synergism with chemo- and radiotherapy anti-metastatic? efficacy? longterm treatment, side effects? resistance afterall? lymphangiogenesis - lymph node metastasis inflammation! Reviews: Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002 Apr;1(3):219-27. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002 Aug;2(8):573-83. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003 Jun;3(6):401-10. Ferrara N, Gerber HP, LeCouter J.The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669-76. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002 Oct;2(10):795-803. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007 Apr;6(4):273-86.